The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C. S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920022/
https://ncbi.nlm.nih.gov/pubmed/27069256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-688796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados